A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia

Francis J. Giles, Jorge E. Cortes, Hagop M. Kantarjian, Susan M. O'Brien, Elihu Estey, Miloslav Beran

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

As fludarabine, topotecan and cytarabine (ara-C) are effective in acute myeloid leukemia (AML), a pilot study of these three agents combined (FTA) was conducted. FTA consisted of topotecan 1.25mg/m2 by CIV days 1-5, fludarabine 15mg/m2 and ara-C 0.5g/m2 IV, BID, on days 2-6. Seventeen patients (6 primary resistant, 11 relapsed) with AML received 33 courses of FTA. Six patients (35%) achieved complete remission. Seven patients (41%) developed grade 3 or 4 diarrhea. FTA was effective and warrants further study in patients with refractory AML.

Original languageEnglish (US)
Pages (from-to)353-357
Number of pages5
JournalLeukemia Research
Volume28
Issue number4
DOIs
StatePublished - Apr 2004
Externally publishedYes

Keywords

  • Acute myeloid leukemia
  • Cytarabine
  • Fludarabine
  • Refractory
  • Topotecan

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia'. Together they form a unique fingerprint.

  • Cite this